Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Year: 2019
Type: erratum
Source: British Journal of Cancer
Authors: César Serrano, Adrián Mariño-Enríquez, Derrick L. Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M. Mannan, Brian P. Rubin, George D. Demetri, Chandrajit P. Raut, Ajia Presnell, Arin McKinley, Michael C. Heinrich, Jeffrey T. Czaplinski, Ewa Sicinska, Sebastian Bauer, Suzanne George, Jonathan A. Fletcher
Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Essen University Hospital, University of Duisburg-Essen, Broad Institute, Daiichi Sankyo (United States), Cleveland Clinic, Cleveland Clinic Research, Dana-Farber/Harvard Cancer Center, Oregon Health & Science University, Portland VA Medical Center, OHSU Knight Cancer Institute
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2954943907